The recommendations and remarks contained in this document were formulated by three different Guideline Development Groups (GDGs) convened by the Global TB Programme (GTB) of the World Health Organization (WHO) in Geneva, Switzerland. The original documents were: Guideline update on management of drug-resistant TB, 2011; Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update; and WHO consolidated guidelines on tuberculosis. Module 5: Management of tuberculosis in children and adolescents, 2022. WHO gratefully acknowledges the contributions of the members of the GDGs, individual experts and partners who were involved in the production of these guidelines.

Details of the participants and members of GDGs, external review groups, WHO steering groups, evidence review teams, individuals and partners who contributed to the 2011, 2017 and 2022 guideline updates are included in Annex 1.

The consolidation of recommendations and the production of this document – WHO consolidated guidelines on tuberculosis. Module 4: Treatment. Tuberculosis care and support – were coordinated by Fuad Mirzayev and Linh Nguyen, under the guidance of Matteo Zignol and the overall direction of Tereza Kasaeva, Director of the WHO Global Tuberculosis Programme. Colleagues from the Vulnerable Populations, Communities and Co-morbidities Unit, Global TB Programme, WHO, under the leadership of Farai Mavhunga, also contributed to the consolidation of these guidelines.

The development of this document was funded by grants provided to WHO by the United States Agency for International Development.

Book navigation